P - Contraindicated in Pregnancy
L - Contraindicated in Lactation
LI - Lab *
Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction to inhibit premature luteinizing hormone surges.
Cetrorelix, a synthetic decapeptide analog of naturally occurring gonadorelin, is a gonadorelin antagonist. It competitively blocks gonadorelin receptors on the anterior piyuitary gonadotroph and the subsequent transduction pathway, inducing a rapid, reversible suppression of gonadotrophin secretion.
Duration: 4 days for a single 3-mg dose.
In Assisted reproductive technologies.
Mild and transient reactions at Inj site, nausea, headache, ovarian hyperstimulation syndrome, systemic hypersensitivity reactions.
Women with active allergic conditions or a history of allergies; childn; elderly >65 yrs.
Assisted reproductive technologies
Adult: As acetate: equiv to 0.25 mg cetrorelix either in the morning beginning on the day 5 or 6 of ovarian stimulation or in the evening beginning on day 5, and continued until ovulation induction. Alternatively, a single dose equiv to 3 mg cetrorelix on day 7,; if follicle growth does not allow ovulation induction within 4 days, additional doses of 250 mcg once daily may be given until the day of ovulation induction.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.
Hypersensitivity. Moderate to severe renal or hepatic impairment. Women with severe allergic conditions. Pregnancy and lactation.
Information Not Available.